The diagnostic model identifies key microRNAs that may affect breast cancer treatment outcomes, particularly regarding DNA damage sensitivity.
The investigation highlighted the significant role of the miR-139-3p/RPA2 axis in regulating responses to DNA-damaging drugs.
Assessment utilizing liquid biopsy techniques allows for less invasive diagnosis and monitoring of breast cancer.
Targeting microRNA pathways may enable new therapeutic strategies, yet further validation is needed for clinical application.
Abstract
The diagnostic model based on the four circulating miRNAs could serve as a tool for the liquid biopsy of BC. Targeting the miR-139-3p/RPA2 axis may have potential in modulating the DNA damage pathway in BC.